The first 100% effective HIV prevention drug is approved and going global

The FDA has approved Yeztugo, a revolutionary HIV prevention drug providing near-complete protection through biannual injections. This lenacapavir-based medication by Gilead Sciences may transform HIV prevention by addressing adherence and stigma issues. Gilead is ensuring global access, partnering with the Global Fund to supply doses for up to two million people in high-risk, resource-limited countries at cost. The company has also arranged for generic production in 120 countries. This breakthrough could potentially end the HIV epidemic, saving millions of lives globally.